Current sales price of capmatinib

Capmatinib (Capmatinib) is a tyrosine kinase inhibitor that targets MET gene mutations. It is mainly used to treat patients with non-small cell lung cancer (NSCLC) accompanied by METexon 14 skipping mutations. At present, this drug has been successfully launched in China and has been included in the medical insurance system. For eligible patients, medical insurance reimbursement can alleviate a large part of the financial burden. However, due to its short time on the market, hospitals or pharmacies in some areas may not have fully distributed the drug, and patients may still face a certain waiting time or unstable supply when purchasing drugs domestically.

In terms of price, capmatinib is sold as an original drug in China, and the overall price is relatively high. In the absence of medical insurance reimbursement, the price of a box of drugs usually ranges from tens of thousands of yuan, and the specific amount will fluctuate depending on the specifications (such as200mg*60tablets), hospital channels and regions. After being included in medical insurance, some patients can be reimbursed through medical insurance according to different local policies, and the actual out-of-pocket payment ratio has been significantly reduced, reducing the financial pressure of long-term medication. Therefore, it is recommended that patients confirm the relevant reimbursement scope and proportion with the local medical insurance department or hospital before taking medication.

In addition to purchasing drugs domestically, some patients will also consider obtaining capmatinib through overseas channels. In overseas markets, especially in European and American countries, the price of capmatinib’s original drug is still at a high level. The price per box is usually around tens of thousands of yuan, and the overall cost is no less than that in China. Against this background, generic drugs produced in some countries such as Laos have gradually attracted the attention of patients. The price of the Lao version of capmatinib generic drug is relatively affordable, with each box selling for about more than 2,000 yuan, and its drug ingredients are consistent with the original drug, making it a feasible option for many patients to reduce treatment costs.

Overall, as a precision targeted drug, capmatinib’s clinical value is increasingly evident, but its high price is still an important consideration in patients’ medication decisions. With the gradual advancement of domestic medical insurance coverage and the price advantage of overseas generic drugs, patients can flexibly choose according to their own condition, economic conditions and drug purchase channels under the guidance of doctors, thereby achieving a balance between efficacy and cost. In the future, as drug supply gradually stabilizes and more generic versions are launched, the overall accessibility of capmatinib is expected to further improve.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib